updat
antivir
therapi
rebecca
p
wilk
antivir
chemotherapi
use
still
rel
uncommon
veterinari
medicin
control
studi
evalu
efficaci
antivir
drug
cat
lack
studi
done
mani
case
data
insuffici
determin
effect
dose
drug
except
recombin
felin
interferon
rfeifn
omega
far
antivir
drug
specif
licens
veterinari
medicin
leav
veterinari
commun
option
use
offlabel
antivir
made
human
combat
viral
diseas
felin
patient
goal
research
antivir
chemotherapi
discoveri
antivir
agent
specif
inhibit
viral
multipl
without
affect
normal
cell
divis
howev
virus
depend
host
cell
machineri
replic
drug
target
often
nonspecif
make
antivir
inher
toxic
antimicrobi
antivir
drug
damag
viru
also
host
cell
well
addit
agent
consid
safe
human
use
alway
safe
administ
cat
antivir
made
system
use
often
requir
host
viral
metabol
activ
therefor
agent
design
use
human
neither
reliabl
predict
metabol
cat
virus
thu
antivir
agent
alway
test
first
vitro
efficaci
safeti
follow
pharmacokinet
studi
cat
system
antivir
often
rel
narrow
safeti
margin
special
consider
alway
given
patient
reduc
hepat
renal
function
welldesign
blind
placebocontrol
studi
clientown
anim
follow
studi
laboratorybr
experiment
infect
cat
confirm
result
genet
divers
cat
human
antivir
specif
intend
treatment
human
immunodefici
viru
hiv
human
herpesviru
infect
therefor
felin
immunodefici
viru
fiv
felin
herpesviru
type
infect
import
indic
antivir
chemotherapi
veterinari
medicin
topic
antivir
therapi
mainli
use
herpet
ocular
diseas
studi
evalu
system
antivir
compound
famciclovir
treatment
multipl
clinic
syndrom
associ
infect
even
though
combin
antivir
therapi
success
slow
diseas
progress
peopl
hiv
similar
therapi
thoroughli
evalu
cat
recent
studi
focus
combin
therapi
evalu
addit
hiv
drug
previous
evalu
felin
cell
hope
expand
number
drug
shown
effect
fiv
lead
effect
combin
therapi
felin
patient
addit
felin
infect
focu
current
antivir
studi
felin
leukemia
viru
felv
infect
felin
infecti
periton
fip
hiv
antivir
raltegravir
nonspecif
display
activ
addit
retrovirus
includ
felv
vitro
studi
identif
human
coronaviru
caus
sever
acut
respiratori
syndrom
sar
led
evalu
antivir
treatment
variou
coronavirus
includ
felin
coronavirus
fcov
caus
fip
although
test
mainli
vitro
stage
sever
studi
also
evalu
use
rfeifnomega
treatment
multipl
felin
virus
review
literatur
antivir
treatment
cat
includ
current
recommend
drug
dosag
use
given
tabl
felin
immunodefici
viru
infect
lymphocyt
cell
monocytemacrophag
lineag
cell
central
nervou
system
caus
varieti
clinic
sign
figur
viral
replic
cycl
fiv
highli
similar
hiv
felin
immunodefici
viru
bind
host
cell
initi
interact
fiv
envelop
env
glycoprotein
molecul
host
cell
result
subsequ
interact
coreceptor
host
cell
follow
viral
envelop
fusion
host
cell
membran
allow
entri
viral
nucleocapsid
cytoplasm
viral
rna
releas
cytoplasm
transcrib
complementari
dna
cdna
revers
transcriptas
rt
enzym
specif
retrovirus
cdna
subsequ
synthes
doublestrand
dna
transport
nucleu
integr
host
genom
anoth
virusspecif
enzym
integras
viral
messeng
ribonucl
acid
mrna
genom
rna
transcrib
transport
cytoplasm
viral
protein
translat
process
third
virusspecif
enzym
proteas
immatur
virion
move
cell
membran
acquir
viral
envelop
glycoprotein
final
releas
cell
antiretrovir
drug
studi
extens
hiv
infect
target
three
virusspecif
enzym
proteas
rt
integras
well
addit
target
interf
differ
step
viru
replic
cycl
approxim
compound
approv
us
food
drug
administr
fda
treatment
differ
stage
hiv
infect
drug
also
use
fiv
step
inhibit
includ
viru
entri
suscept
cell
block
attach
host
cell
coreceptor
revers
transcript
viral
genom
rna
viral
dna
integr
host
genom
proteolyt
process
precursor
viral
protein
matur
viral
protein
figur
dose
indic
close
similar
exist
rt
hiv
fiv
shown
sever
rttarget
antivir
compound
activ
hiv
also
effect
inhibit
fiv
replic
vitro
rt
hiv
actual
target
three
class
inhibitor
nucleosid
rt
inhibitor
nrti
nucleotid
rt
inhibitor
ntrti
nonnucleosid
rt
inhibitor
nnrti
nucleosid
rt
inhibitor
ntrti
interact
catalyt
site
substratebind
site
rt
enzym
wherea
nnrti
interact
alloster
site
locat
short
distanc
catalyt
site
nrti
ntrti
interact
substratebind
site
need
phosphoryl
emtricitabin
consid
nucleosid
analogu
act
similar
fashion
taken
cell
phosphoryl
three
time
activ
triphosph
form
act
competit
inhibitor
normal
deoxynucleosid
triphosph
dntp
substrat
use
cell
make
dna
unlik
dntp
substrat
nrti
lack
group
deoxyribos
moieti
incorpor
dna
chain
absenc
group
normal
form
bond
next
nucleic
acid
block
extens
dna
rt
result
dna
chain
termin
analogu
cleav
activ
center
thu
block
rt
enzym
nucleosid
analogu
accept
fals
substrat
viral
enzym
also
cellular
enzym
infecti
diseas
mononuclear
cell
six
drug
abc
ddi
emtricitabin
azt
previous
evalu
felin
cell
three
amdoxovir
racivir
dexelvucitabin
signific
differ
among
drug
found
base
data
obtain
amdoxovir
dexelvucitabin
racivir
appear
option
futur
studi
investig
potenti
use
fivinfect
cat
though
pharmacolog
data
cat
avail
drug
cytotox
properti
compound
suggest
could
like
use
vivo
dosag
compar
azt
nucleotid
rt
inhibitor
distinguish
nrti
nucleotid
analogu
nucleosid
analogu
mean
need
two
three
phosphoryl
step
convert
activ
form
importantli
contain
phosphon
group
cleav
hydrolas
esteras
would
make
difficult
cleav
compound
incorpor
end
compar
regular
nucleotid
counterpart
use
compound
also
result
dna
chain
termin
one
drug
cidofovir
activ
virtual
dna
virus
includ
polyoma
papilloma
adeno
herp
poxvirus
cidofovir
use
treatment
see
felin
herpesviru
type
adefovir
adenin
pmea
spectrum
activ
partial
overlap
cidofovir
activ
herpesvirus
adefovir
also
activ
hepadnavirus
hepat
b
retrovirus
includ
fiv
felv
antivir
activ
spectrum
tenofovir
pmpa
narrow
pmea
longer
extend
herpesvirus
confin
hepadnaand
retrovirus
drug
test
vitro
felv
see
felin
leukemia
viru
adefovir
test
fivinfect
cat
placebocontrol
doubleblind
clinic
trial
cat
receiv
adefovir
mgkg
subcutan
sc
twice
weekli
cat
receiv
placebo
decreas
provir
viral
load
treat
cat
cat
develop
progress
lifethreaten
anemia
common
advers
effect
nucleotid
analogu
adefovir
also
test
combin
coreceptor
inhibitor
plerixafor
see
coreceptor
inhibitor
studi
produc
outcom
seen
use
adefovir
alon
relat
drug
r
pmpdap
shown
previous
potent
inhibitor
fiv
replic
cell
cultur
reduc
viral
load
three
four
cat
experiment
infect
fiv
treat
mgkg
sc
three
time
per
week
week
chang
red
blood
cell
count
hemoglobin
valu
treatment
recent
studi
evalu
efficaci
drug
placebocontrol
doubleblind
studi
popul
cat
natur
infect
fiv
signific
differ
found
pmpdaptreat
mgkg
sc
twice
weekli
week
placebotr
cat
although
cat
treat
pmpdap
show
tendenc
improv
major
caus
toxic
zidovudin
nrti
studi
cat
includ
vivo
studi
evalu
clinic
respons
experiment
natur
fivinfect
cat
treat
drug
zidovudin
increas
ratio
improv
clinic
condit
score
fivinfect
cat
howev
result
advers
effect
dosedepend
nonregen
anemia
neutropenia
addit
mutat
produc
resist
drug
develop
therefor
studi
evalu
nine
nrti
inhibit
fiv
replic
felin
peripher
blood
receptor
coreceptor
protein
dna
signific
decreas
proviru
load
lead
improv
clinic
immunolog
variabl
statist
decreas
serum
magnesium
level
observ
treatment
group
without
clinic
consequ
develop
resist
fiv
isol
plerixafor
found
treatment
period
make
potenti
treatment
fivinfect
cat
limit
oral
bioavail
short
halflif
preclud
clinic
use
plerixafor
hiv
infect
addit
antagonist
develop
test
efficaci
fiv
avail
integras
catalyz
strand
transfer
join
insert
viral
dna
end
host
cell
chromosom
integras
inhibitor
use
treat
hiv
infect
one
integras
inhibitor
raltegravir
shown
effect
inhibit
felv
see
felin
leukemia
viru
administr
combin
drug
differ
class
term
highli
activ
antiretrovir
therapi
haart
hivinfect
patient
turn
invari
fatal
diseas
chronic
manag
condit
goal
associ
use
combin
three
antihiv
compound
obtain
synerg
among
differ
compound
act
differ
molecular
target
lower
individu
drug
dosag
reduc
advers
side
effect
diminish
likelihood
develop
drug
resist
combin
therapi
thoroughli
investig
treatment
fiv
infect
cat
use
multipl
class
drug
difficult
cat
drug
class
effect
hiv
work
fiv
howev
need
combin
antiretrovir
therapi
felin
patient
focu
recent
studi
goal
antivir
therapi
improv
cat
clinic
statu
alway
correl
viru
replic
measur
plasma
viral
load
suggest
antiretrovir
therapi
administ
fivinfect
cat
later
stage
asymptomat
phase
infect
cat
show
clinic
sign
immun
system
rel
normal
like
respond
treatment
experiment
infect
ratio
decreas
viral
load
increas
markedli
clinic
sign
immunosuppress
begin
appear
howev
situat
natur
infect
cat
differ
qualiti
life
associ
viral
load
therefor
debat
time
point
antivir
therapi
start
whether
administ
asymptomat
cat
recent
studi
antiretrovir
therapi
initi
later
stage
asymptomat
phase
infect
natur
infect
cat
cat
defin
later
stage
clinic
sign
ratio
mild
hematolog
side
effect
slight
declin
pack
cell
volum
hemoglobin
valu
seen
treatment
group
compar
ntrti
pmpdap
seem
slightli
less
toxic
unlik
nrti
ntrti
nnrti
activ
form
depend
intracellular
metabol
pathway
nnrti
inhibit
rt
bind
enzym
hydrophob
pocket
locat
away
catalyt
site
interact
compound
rt
induc
conform
chang
affect
catalyt
activ
enzym
nonnucleosid
rt
inhibitor
consid
highli
specif
inhibitor
thu
activ
retrovirus
includ
fiv
due
differ
structur
andor
flexibl
fiv
rt
prevent
nnrti
interact
fiv
rt
proteas
inhibitor
base
peptidomimet
principl
contain
hydroxyethylen
scaffold
mimic
normal
peptid
linkag
cleav
hiv
proteas
cleav
thu
prevent
hiv
proteas
carri
normal
function
proteolyt
process
precursor
viral
protein
matur
viral
protein
despit
similar
hiv
fiv
proteas
one
current
avail
hiv
proteas
inhibitor
fail
inhibit
proteas
fiv
one
compound
interest
tipranavir
test
fiv
vitro
far
howev
studi
demonstr
compound
use
inhibit
fcov
replic
see
felin
coronaviru
coreceptor
inhibitor
block
viral
attach
bind
receptor
host
cell
membran
obscur
site
interact
env
receptor
receptor
homologu
antagonist
highli
select
hiv
use
veterinari
medicin
one
except
use
cat
fiv
infect
class
bicyclam
eg
plerixafor
plerixafor
bi
octachlorid
dehydr
prototyp
compound
among
bicyclam
bicyclam
dimer
lowmolecular
weight
nonpeptid
compound
bind
select
chemokin
receptor
cell
surfac
coreceptor
use
hiv
fiv
attach
infect
suscept
lymphocyt
amino
acid
sequenc
human
felin
highli
similar
drug
bind
inhibit
attach
viral
envelop
host
cell
efficaci
plerixafor
fiv
recent
investig
natur
fivinfect
cat
treat
placebocontrol
doubleblind
clinic
trial
plerixafor
administ
mgkg
sc
everi
hour
treatment
fivinfect
cat
plerixafor
caus
infecti
diseas
agricultur
usda
treatment
aid
cat
infect
fiv
felv
primari
therapeut
effect
activ
progenitor
tcell
matur
cell
produc
cytokin
includ
interleukin
il
interferon
ifn
studi
perform
manufactur
highlight
review
articl
studi
suggest
reduc
viru
load
improv
clinic
sign
improv
hematolog
paramet
treatment
howev
data
placebocontrol
studi
shown
field
studi
natur
infect
cat
lack
control
group
independ
placebocontrol
blind
studi
warrant
addit
inform
immunomodul
immunostimul
provid
felin
herpesviru
type
felin
coronaviru
section
felin
leukemia
viru
like
fiv
member
famili
retrovirida
unlik
fiv
felv
gammaretroviru
lentiviru
felin
leukemia
viru
caus
wide
varieti
clinic
sign
infect
cat
figur
structur
differ
affect
suscept
gammaretrovirus
antihiv
drug
similar
mechan
replic
suggest
drug
also
inhibit
felv
true
nrti
zidovudin
effect
inhibit
felv
replic
vitro
vivo
experiment
infect
howev
natur
felvinfect
cat
reduc
plasma
viru
load
improv
immunolog
clinic
statu
increas
qualiti
life
prolong
life
expect
bone
marrow
toxic
also
caus
advers
side
effect
eg
nonregen
anemia
pronounc
felvinfect
cat
fivinfect
cat
therefor
recommend
first
line
therapi
felv
infect
asymptomat
phase
infect
ratio
reach
stage
infect
viral
load
increas
markedli
clinic
sign
immunosuppress
began
appear
ratio
calcul
everi
month
year
prior
initi
antivir
therapi
viral
load
cat
quantifi
year
cat
randomli
assign
treatment
group
eight
cat
treatment
includ
combin
therapi
placebo
group
use
studi
blind
followup
perform
year
clinic
evalu
determin
viral
load
ratio
comparison
pretreat
posttreat
valu
cat
perform
well
comparison
valu
treatment
group
combin
two
nrti
azt
mgkg
everi
hour
oral
po
compar
treatment
azt
alon
mgkg
everi
hour
po
combin
azt
often
use
hivinfect
patient
given
drug
show
synergist
effect
treatment
azt
alon
combin
induc
signific
increas
ratio
signific
decreas
viral
load
within
among
group
even
greater
reduct
combin
therapi
azt
alon
mild
side
effect
includ
vomit
one
eight
cat
anorexia
two
eight
cat
anemia
one
eight
cat
seen
treatment
combin
therapeut
intervent
resolv
problem
treatment
stop
howev
lack
control
group
lack
blind
make
result
studi
difficult
interpret
therefor
treatment
asymptomat
fivinfect
cat
antivir
gener
recommend
base
current
avail
data
earlier
vivo
studi
perform
experiment
fivinfect
cat
treat
highdos
azt
combin
mgkgday
po
drug
combin
antifiv
activ
chronic
infect
cat
sever
side
effect
includ
fever
anorexia
mark
hematolog
chang
observ
cat
highdos
dualdrug
treatment
toxic
effect
revers
dose
lower
mgkg
everi
hour
ideal
combin
therapi
felin
patient
contain
least
two
three
drug
least
two
differ
class
recommend
human
patient
previous
mention
pmea
ntrti
test
combin
coreceptor
inhibitor
plerixafor
howev
toxic
associ
pmea
combin
recommend
therefor
use
plerixafor
combin
ntrti
less
toxic
pmea
compound
drug
class
investig
futur
lymphocyt
tcell
immunomodul
ltci
protein
produc
bovinederiv
thymic
stromal
epitheli
cell
line
condit
licens
unit
state
depart
alphaherpesvirus
herp
simplex
viru
investig
treatment
member
group
antivir
agent
includ
acyclovir
prodrug
valacyclovir
ganciclovir
penciclovir
prodrug
famciclovir
requir
three
phosphoryl
step
activ
first
step
must
catalyz
viral
enzym
thymidin
kinas
make
drug
less
toxic
vivo
compar
mani
antivir
drug
howev
activ
thymidin
kinas
equival
enzym
human
herpesvirus
second
third
phosphoryl
step
must
perform
host
enzym
effect
cat
human
knowledg
help
explain
acycl
nucleosid
antivir
agent
develop
human
infect
predict
effect
administ
cat
infect
pharmacokinet
efficaci
studi
alway
need
establish
appropri
dose
cat
acyclovir
adequ
test
cat
treatment
rel
low
antivir
potenc
poor
bioavail
high
dose
requir
effect
treatment
associ
unaccept
toxic
sign
relat
bone
marrow
suppress
nephrotox
prodrug
acyclovir
valacyclovir
develop
increas
bioavail
human
use
treatment
experiment
infect
cat
induc
fatal
renal
hepat
necrosi
bone
marrow
suppress
reduc
viral
shed
clinic
diseas
sever
therefor
despit
superior
pharmacokinet
valacyclovir
use
cat
ganciclovir
appear
least
effect
acyclovir
vitro
ganciclovir
avail
system
well
topic
use
form
ophthalm
gel
formul
human
ganciclovir
hold
promis
felin
infect
current
avail
formul
warrant
safeti
efficaci
studi
cat
tenofovir
ntrti
use
treatment
hiv
shown
effect
felv
vitro
antifelv
mechan
tenofovir
probabl
similar
describ
tenofovir
given
form
prodrug
convert
acycl
nucleosid
phosphat
convert
activ
diphosph
form
tenofovir
incorpor
rt
viral
dna
act
chain
termin
inhibit
elong
viral
dna
howev
vivo
studi
felvinfect
cat
lack
anoth
compound
current
use
human
hiv
therapi
raltegravir
could
consid
treatment
felvinfect
cat
high
degre
conserv
across
lentivirus
betaretrovirus
gammaretrovirus
alpharetrovirus
integras
activ
site
suggest
felv
might
highli
sensit
integras
inhibitor
mechan
action
felv
fiv
inhibit
integr
viral
dsdna
produc
revers
transcript
viral
rna
genom
vitro
studi
evalu
effect
inhibitori
concentr
ec
felv
inhibit
raltegravir
sever
felin
cell
line
found
valu
rang
observ
hiv
relat
gammaretroviru
xenotrop
murin
leukemia
viru
well
minim
plasma
concentr
found
human
effect
concentr
raltegravir
appreci
effect
cell
viabil
induc
apoptosi
suggest
could
effect
safe
drug
also
vivo
howev
raltegravir
partli
elimin
glucuronid
metabol
pathway
effici
cat
would
increas
risk
toxic
result
drug
accumul
vivo
studi
publish
felin
herpesviru
type
member
subfamili
alphaherpesvirina
order
herpesviral
herp
simplex
virus
varicella
zoster
viru
also
member
subfamili
antivir
develop
treatment
human
virus
use
treatment
cat
felin
herpesviru
type
typic
infect
epitheli
mucos
surfac
travel
retrograd
along
sensori
axon
establish
latenc
trigemin
ganglia
reactiv
viru
travel
axon
infect
similar
tissu
origin
infect
potenti
result
recurr
chronic
sequela
includ
kerat
conjunct
rhinosinus
dermat
figur
potenti
blind
wherea
drug
combin
becom
standard
procedur
treatment
hiv
infect
treatment
viru
infect
includ
herpesvirus
routin
base
use
singl
antivir
drug
group
antivir
drug
known
acycl
nucleosid
analogu
use
system
treatment
human
effect
potenti
altern
therapi
use
topic
drug
major
requir
multipl
daili
applic
howev
implant
silicon
polym
devic
impregn
penciclovir
develop
hold
promis
longterm
steadyst
subconjunctiv
deliveri
drug
treatment
ocular
herpet
diseas
although
herpet
ocular
diseas
commonli
treat
topic
antivir
ophthalm
solut
ointment
includ
idoxuridin
vidarabin
trifluridin
antivir
requir
virusspecif
phosphoryl
step
activ
moreov
damag
host
cell
specif
result
bone
marrow
suppress
therefor
use
system
good
review
topic
drug
see
report
magg
gould
cidofovir
member
ntrti
class
drug
test
topic
treatment
ocular
diseas
system
use
appear
efficaci
topic
newer
drug
therefor
includ
section
cidofovir
requir
typic
two
hostmedi
phosphoryl
step
without
viral
mediat
phosphoryl
safeti
given
topic
aris
rel
high
affin
hsv
dna
polymeras
compar
human
dna
polymeras
commerci
avail
inject
form
unit
state
treatment
human
betaherpesviru
appli
topic
solut
twice
daili
cat
experiment
infect
led
reduc
viral
shed
improv
clinic
diseas
compar
placebo
group
efficaci
twice
daili
administr
despit
virostat
believ
due
long
tissu
halfliv
metabolit
drug
report
experiment
topic
use
human
rabbit
associ
stenosi
nasolacrim
duct
shown
cat
fact
twicedaili
topic
treatment
suffici
wherea
topic
antivir
requir
applic
everi
hour
make
cidofovir
use
altern
ocular
topic
treatment
small
interf
rna
small
interf
rna
sirna
design
target
dna
polymeras
glycoprotein
use
vitro
induc
rna
interfer
immort
cell
line
primari
felin
corneal
epitheli
cell
inhibit
replic
rna
interfer
posttranscript
rnaguid
genesilenc
mechan
present
eukaryot
interfer
essenti
gene
result
reduct
viru
replic
type
therapi
intend
topic
treatment
chronic
herpet
diseas
howev
preliminari
vivo
studi
evalu
topic
deliveri
sirna
felin
cornea
unsuccess
lack
deliveri
like
result
sirna
dilut
rapid
remov
tear
film
blink
studi
ongo
identifi
mean
increas
promis
system
drug
treatment
famciclovir
prodrug
activ
compound
penciclovir
shown
highli
efficaci
inhibit
replic
vitro
penciclovir
absorb
poorli
given
oral
oral
form
famciclovir
develop
increas
bioavail
uptak
intestin
tract
famciclovir
requir
dideacetyl
mainli
blood
oxid
hepat
aldehyd
oxidas
convers
activ
compound
penciclovir
unfortun
hepat
aldehyd
oxidas
activ
basic
absent
cat
make
pharmacokinet
drug
complex
result
lower
expect
plasma
penciclovir
concentr
despit
administr
rel
high
dose
famciclovir
despit
studi
evalu
famciclovir
vivo
shown
safe
efficaci
use
felin
patient
cat
experiment
infect
receiv
famciclovir
mgkg
po
three
time
daili
day
significantli
improv
outcom
system
ophthalm
clinicopatholog
virolog
serolog
histolog
variabl
compar
placebotr
cat
treatment
initi
day
zero
day
cat
infect
even
though
studi
mimic
cat
natur
infect
would
treat
result
clinic
case
studi
suggest
drug
like
effect
treatment
clinic
case
though
blind
placebo
control
clinic
case
primari
ocular
diseas
rhinosinus
dermat
attribut
though
definit
diagnos
treat
famciclovir
dose
mg
po
twice
daili
ocular
herpet
diseas
rhinosinus
mg
po
three
time
daili
dermat
famciclovir
well
toler
dose
posit
effect
clinic
condit
definit
dose
rate
establish
famciclovir
howev
penciclovir
appreci
vitro
effect
present
hour
prior
infect
suggest
famciclovir
administ
frequent
everi
hour
ensur
exposur
penciclovir
addit
epitheli
cell
becom
expos
viral
infect
current
pharmacokinet
data
suggest
dose
three
time
daili
requir
mgkg
po
three
time
daili
suggest
treatment
cat
infect
base
effect
concentr
obtain
vivo
studi
determin
new
vitro
inhibitori
concentr
commonli
report
advers
effect
famciclovir
treatment
human
includ
urticaria
hallucin
headach
confus
especi
elderli
human
would
like
difficult
detect
anim
reason
judici
use
drug
recommend
clientown
cat
especi
preexist
hepat
renal
insuffici
pharmacokinet
studi
also
evalu
concentr
penciclovir
tear
treatment
oral
dose
mg
famciclovirkg
three
time
daili
achiev
penciclovir
concentr
ocular
surfac
like
bolu
ad
food
benefit
lysin
therapi
like
possibl
daili
lifelong
treatment
cat
chronic
herpet
diseas
rather
use
lysin
treatment
acut
recrudesc
episod
potenti
daili
therapi
would
reduc
episod
viral
recrudesc
howev
clinic
studi
pet
cat
lack
cost
therapi
weigh
potenti
benefit
owner
made
awar
adjunct
therapi
administr
antivir
drug
might
necessari
gain
better
control
sign
polyprenyl
immunostimul
pi
immunomodul
condit
licens
unit
state
treatment
infect
blind
placebocontrol
experiment
challeng
studi
pi
start
day
viru
exposur
significantli
reduc
sever
durat
rhiniti
conjunct
associ
acut
diseas
legendr
kuritz
manuscript
prepar
accord
manufactur
pi
upregul
innat
immun
system
modul
immun
respons
toward
cellular
respons
activ
attribut
posit
effect
associ
treatment
requir
cellmedi
immun
respons
control
viral
titer
compar
treatment
control
group
studi
base
reduc
sign
associ
treatment
clinic
studi
warrant
felin
infecti
periton
associ
clinic
sign
affect
almost
bodi
system
figur
current
effect
treatment
fip
despit
import
lead
infecti
caus
death
young
cat
follow
discoveri
sar
caus
coronaviru
sarscov
effort
find
antivir
drug
coronavirus
increas
antivir
agent
target
differ
step
replic
cycl
test
felin
fcov
coronaviru
spike
protein
viral
envelop
initi
bind
receptor
host
cell
membran
spike
protein
mediat
fusion
viral
envelop
host
cell
membran
process
heptad
repeat
spike
protein
assembl
form
complex
result
conform
chang
necessari
fusion
peptid
use
antivir
inhibit
interact
thu
prevent
membran
fusion
spike
protein
must
cleav
entri
viru
cytoplasm
felin
coronaviru
infect
depend
cathepsin
b
host
cystein
proteas
found
within
cell
make
like
proteas
respons
spike
protein
cleavag
therefor
cathepsin
b
serv
potenti
target
develop
therapeut
drug
fcov
follow
entri
cell
fcov
produc
viral
polyprotein
process
contact
time
corneal
cell
sirna
allow
deliveri
twicedaili
oral
llysin
bolu
administr
initi
prior
experiment
infect
reduc
sever
conjunct
cat
undergo
primari
infect
llysin
bolu
administr
also
reduc
viral
shed
latent
infect
cat
experiment
infect
follow
chang
husbandri
hous
follow
corticosteroid
administr
vitro
lysin
supplement
led
reduct
replic
arginin
exert
substanti
growthpromot
effect
essenti
amino
acid
viral
protein
synthesi
lysin
antagon
effect
lysin
arginin
competit
inhibit
transport
use
common
transport
system
lysin
induc
arginas
enzym
caus
degrad
arginin
arginin
defici
inhibit
synthesi
infecti
viral
particl
downregul
synthesi
viral
protein
howev
unlik
protocol
human
owner
cat
receiv
lysin
advis
restrict
cat
arginin
intak
feed
diet
lack
larginin
associ
sever
risk
hyperammonemia
encephalopathi
suggest
ratio
llysin
larginin
rather
concentr
amino
acid
critic
achiev
inhibitori
effect
viral
replic
dietari
supplement
increas
mean
plasma
concentr
llysin
without
reduc
larginin
concentr
shown
safe
use
cat
gkg
diet
supplement
higher
dose
shown
result
reduc
food
intak
despit
promis
initi
vitro
data
vivo
result
experiment
studi
current
studi
question
whether
viral
inhibit
increas
lysin
concentr
absenc
decreas
arginin
concentr
biolog
import
new
studi
evalu
effect
variou
ratio
llysin
larginin
dna
replic
vitro
demonstr
modest
reduct
viral
dna
less
log
ratio
consid
difficult
obtain
vivo
healthi
cat
lack
efficaci
llysin
supplement
also
demonstr
vivo
shelter
set
dietari
supplement
unsuccess
like
cat
anorex
peak
diseas
ingest
lysin
need
bolu
administr
also
unsuccess
like
stress
associ
lysin
administr
stress
bolu
administr
shelter
situat
could
negat
effect
even
caus
transfer
pathogen
among
cat
shelter
worker
administ
lysin
howev
data
support
dietari
supplement
unfortun
studi
date
conduct
clientown
cat
howev
anecdot
evid
suggest
benefit
administr
lysin
individu
dose
mg
po
twice
daili
given
infecti
diseas
ment
host
cell
antivir
effect
concentr
depend
nelfinavir
display
cellular
toxic
higher
dose
gna
better
inhibitor
fcov
two
agent
ad
togeth
synergist
antivir
effect
produc
result
suggest
combin
use
gna
nelfinavir
could
therapeut
potenti
treatment
cat
fip
viral
fusion
also
target
effect
synthet
peptid
base
put
sequenc
fcov
viru
replic
significantli
inhibit
vitro
compar
control
peptid
nontox
peptid
also
use
combin
human
ifnalpha
two
display
synergist
effect
cell
pretreat
ifn
prior
infect
viru
see
section
interferon
inform
interferon
treatment
fip
immunomodul
consid
fip
immunemedi
diseas
drug
shown
promis
immunomodul
pi
drug
condit
licens
unit
state
treatment
infect
case
seri
three
cat
pi
associ
prolong
surviv
cat
noneffus
fip
placebo
group
includ
comparison
definit
conclus
effect
drug
treatment
fip
drawn
addit
immunostimul
immunoregulin
propionibacterium
acn
inactiv
bacterin
tcell
receptor
peptid
manufactur
imulan
biotherapeut
suggest
treatment
fip
antivir
drug
instead
product
report
stimul
immun
respons
toward
cellmedi
respons
reduc
overact
type
helper
tcell
respons
imbal
tcell
versu
bcell
immun
respons
suggest
contribut
develop
fip
propos
strong
cellmedi
immun
respons
protect
cat
develop
fip
wherea
product
antibodi
counterproduct
enhanc
uptak
replic
felin
infecti
periton
viru
fipv
macrophag
contribut
patholog
produc
type
iii
hypersensit
vascul
howev
hypothesi
question
therefor
even
though
use
type
drug
stimul
cellmedi
respons
might
seem
logic
approach
treatment
fip
current
data
support
use
addit
nonantivir
drug
evalu
treatment
fip
propentofyllin
drug
appear
downregul
proinflammatori
cytokin
turn
reduc
vascul
vascul
state
earlier
respons
patholog
associ
fip
howev
placebocontrol
doubleblind
studi
cat
late
stage
fip
matur
protein
viralspecif
proteas
main
proteas
proteas
papainlik
proteas
cleavag
viral
polyprotein
essenti
step
viru
replic
blockag
viral
proteas
also
attract
target
therapeut
intervent
vitro
experi
crandellre
felin
kidney
cell
proteas
inhibitor
cathepsin
inhibitor
test
abil
inhibit
fcov
replic
type
drug
produc
effect
inhibit
ec
valu
nanomolar
rang
drug
test
nontox
cell
effect
concentr
proteas
inhibitor
effect
cathepsin
inhibitor
use
combin
drug
strong
synerg
effect
vivo
studi
drug
cat
date
one
vitro
studi
antivir
compound
includ
nucleosid
analogu
use
treat
herpesvirus
nrti
use
hiv
proteas
inhibitor
also
use
hiv
test
abil
inhibit
fcov
cell
cultur
among
drug
test
two
show
signific
inhibit
fcov
compar
untreat
cell
nelfinavir
galanthu
nivali
agglutinin
gna
nelfinavir
hiv
proteas
inhibitor
shown
target
proteas
sarscov
interact
residu
proteas
drug
slightli
less
effect
fcov
sarscov
like
seven
correspond
residu
proteas
fcov
ident
sarscov
proteas
gna
carbohydratebind
agent
exhibit
antivir
effect
bind
coronaviru
glycosyl
envelop
glycoprotein
therebi
inhibit
viral
attach
ineffect
within
week
develop
neutral
antibodi
limit
activ
given
oral
longer
period
antibodi
develop
oral
treatment
unlik
rhuifn
rfeifnomega
felin
recombin
product
induc
neutral
antibodi
administ
sc
mean
highdos
parenter
protocol
use
safe
effici
even
repeat
administr
requir
import
factor
consid
condit
manag
need
lifelong
given
po
ifn
inactiv
gastric
acid
destroy
trypsin
proteolyt
enzym
duodenum
therefor
absorb
detect
blood
oral
administr
direct
antivir
effect
unlik
oral
applic
howev
ifn
still
seem
immunomodulatori
activ
type
ifn
like
bind
mucos
receptor
oral
caviti
stimul
local
lymphoid
tissu
lead
cytokin
releas
lymphat
cell
oropharyng
lymphoid
tissu
trigger
cascad
immunolog
respons
act
system
interferon
use
treatment
felin
retroviru
infect
treatment
ifn
improv
clinic
condit
score
cat
infect
felv
fiv
reduct
viral
load
suggest
improv
clinic
condit
seen
treatment
specif
antivir
effect
least
fiv
felv
instead
result
immunomodul
potenti
associ
innat
immun
respons
clinic
sign
fivinfect
cat
caus
immunopatholog
reaction
gingivostomat
uveiti
immunomodul
might
caus
improv
clinic
sign
associ
ifn
treatment
probabl
result
effect
control
inflammatori
cytokin
diseas
organ
suggest
nonspecif
stimul
immun
system
ifn
therapi
might
contraind
fivinfect
cat
could
lead
rise
viral
replic
produc
activ
lymphocyt
macrophag
harbor
latent
infect
therefor
acceler
diseas
progress
cat
use
ifn
hivinfect
human
controversi
howev
use
lowdos
oral
huifn
natur
recombin
studi
ill
fivinfect
cat
iu
per
kg
oral
mucosa
daili
day
altern
week
month
follow
break
repetit
treatment
result
improv
clinic
sign
placebocontrol
doubleblind
studi
parenter
rfeifnomega
use
accord
licens
protocol
tabl
result
decreas
mortal
rate
felvinfect
cat
compar
control
group
anoth
placebocontrol
studi
anoth
studi
evalu
fivandor
felvinfect
cat
hous
shelter
hematolog
valu
remain
within
refer
rang
biochem
abnorm
statist
signific
differ
surviv
time
qualiti
life
clinic
laboratori
paramet
cat
treat
drug
versu
cat
receiv
placebo
cat
studi
cat
display
effus
start
studi
drug
might
use
cat
without
effus
may
chanc
prevent
vascul
therefor
effus
studi
lack
interferon
molecul
produc
vertebr
cell
respons
viral
infect
certain
inert
substanc
doublestrand
rna
microbi
agent
three
type
ifn
type
ifn
compris
largest
subfamili
includ
ifnomega
type
ifn
produc
variou
cell
type
leukocyt
fibroblast
direct
respons
viru
infect
one
member
type
ii
ifn
subfamili
immunomodulatori
cytokin
produc
respons
recognit
infect
cell
lymphocyt
natur
killer
cell
host
immun
system
type
iii
ifn
contain
three
il
identifi
subfamili
also
abil
interfer
viru
replic
suggest
ancestr
antivir
system
vertebr
interferon
virucid
rather
trigger
express
variou
antivir
protein
thu
induc
antivir
state
within
host
cell
limit
replic
spread
virus
type
ifn
shown
potent
enhanc
innat
adapt
immun
respons
vivo
variou
immunomodulatori
effect
activ
dendrit
cell
dc
amplif
antibodi
respons
enhanc
tcell
natur
killer
cell
cytotox
virus
caus
lysi
target
cell
effect
inhibit
ifn
antivir
activ
noninfect
cell
therefor
ifn
highest
util
prophylaxi
earli
postexposur
manag
viru
infect
given
ifn
specif
particular
viru
test
treatment
multipl
felin
virus
includ
fiv
felv
felin
caliciviru
fcv
fcov
two
molecul
type
ifn
current
use
therapi
cat
human
recombin
interferon
alpha
rfeifnomega
licens
use
cat
dog
europ
australia
asian
countri
ifn
strictli
speciesspecif
effect
howev
biolog
activ
toler
greater
cell
genet
relat
speci
vitro
result
suggest
rfeifnomega
would
like
effect
vivo
although
ifn
shown
therapeut
valu
cat
two
common
treatment
regimen
use
cat
inject
high
dose
intern
unit
per
kg
sc
everi
hour
oral
applic
low
dose
intern
unit
iu
per
kg
everi
h
given
parenter
cat
becom
felin
coronaviru
shed
reduc
significantli
enough
fpv
detect
popul
draw
signific
conclus
howev
placebo
group
use
studi
without
placebo
group
difficult
determin
definit
result
due
antivir
effect
ifn
consist
natur
resolut
viral
shed
separ
studi
cat
natur
acquir
upper
respiratori
tract
diseas
hous
human
societi
facil
treat
one
drop
rfeifnomega
solut
unitml
solut
iuml
salin
nacl
solut
catsgroup
eye
twice
daili
day
treatment
keratoconjunct
statist
differ
treatment
group
placebo
group
regard
clinic
score
viral
shed
fcv
determin
realtim
quantit
pcr
oropharyng
conjunctiv
swab
felin
herpesviru
type
shed
lower
though
statist
signific
day
compar
day
group
includ
placebo
group
clinic
score
significantli
decreas
day
compar
day
group
includ
placebo
group
therefor
compar
result
day
treat
cat
without
inclus
placebo
group
would
result
differ
conclus
studi
cat
infect
felv
even
though
fiv
statu
unknown
cat
one
test
neg
howev
studi
highlight
need
placebo
group
accur
evalu
effect
ifn
therapi
fcv
shed
associ
diseas
oral
sc
ifn
therapi
associ
improv
oral
ulcer
gingiv
gingivostomat
cat
infect
fiv
condit
common
cat
fcv
infect
felin
caliciviru
also
associ
chronic
gingivostomat
cat
infect
fiv
felv
studi
evalu
efficaci
rfeifnomega
iuday
day
topic
oromucos
administr
treatment
fcvassoci
felin
chronic
gingivostomat
fcg
caudal
stomat
fiv
felvneg
cat
cat
includ
studi
continu
show
persist
clinic
sign
fcg
least
month
periodont
treatment
scale
subgingiv
polish
tooth
extract
week
antibiot
analges
antiinflammatori
drug
need
twentyfour
cat
treat
ifn
effect
compar
posit
control
group
receiv
standard
corticosteroid
therapi
result
suggest
ifn
therapi
effect
corticosteroid
treatment
condit
improv
clinic
sign
felin
caliciviru
viral
load
evalu
studi
placebo
group
use
comparison
howev
assum
ifn
therapi
caus
improv
seen
cat
result
add
hypothesi
improv
oral
lesion
fivandor
felvinfect
cat
like
associ
effect
ifn
opportunist
viral
infect
differ
outcom
differ
studi
could
due
differ
associ
rfeifnomega
treatment
use
accord
licens
protocol
find
suggest
ifn
treatment
safe
treatment
fivand
felvinfect
cat
studi
requir
clearli
demonstr
efficaci
fiv
felv
vivo
recent
studi
evalu
use
oral
administr
rfeifnomega
treatment
symptomat
natur
infect
clientown
fivinfect
cat
treatment
protocol
iucat
po
everi
hour
consecut
day
administ
cat
owner
histor
group
treat
sc
licens
protocol
use
control
comparison
placebo
group
includ
treatment
result
signific
improv
clinic
score
pretreat
posttreat
valu
signific
differ
sc
histor
control
group
po
group
suggest
po
administr
rfeifnomega
could
use
effect
altern
licens
protocol
significantli
reduc
cost
addit
benefit
use
ifn
therapi
fiv
felv
treatment
could
effect
ifn
opportunist
infect
virus
includ
fcv
fact
effect
ifn
addit
viral
infect
might
caus
improv
clinic
score
associ
ifn
treatment
fiv
felv
replic
lymphoid
monocytoid
cell
subset
caus
immunosuppress
fivinfect
cat
clinic
sign
directli
caus
fiv
result
secondari
infect
well
neoplasia
although
felv
caus
sever
clinic
syndrom
fiv
diseas
secondari
immunosuppress
account
larg
portion
syndrom
seen
felvinfect
cat
well
consid
ifn
therapi
seem
effect
fiv
felv
viru
load
immunomodulatori
would
seem
advis
treat
retrovirusinfect
cat
ifn
clinic
sign
would
benefit
effect
improv
clinic
condit
recent
studi
attempt
evalu
hypothesi
improv
clinic
score
ifn
treatment
fivand
felvinfect
cat
might
reflect
reduct
viral
shed
secondari
virus
cat
sixteen
natur
infect
fivandor
felvinfect
cat
seven
fiv
six
felv
three
coinfect
follow
rfeifnomega
therapi
use
accord
licens
protocol
monitor
clinic
sign
correl
excret
concomit
virus
fcv
fcov
felin
parvoviru
fpv
shed
virus
evalu
realtim
quantit
polymeras
chain
reaction
pcr
fcov
convent
pcr
fcv
fpv
pretreat
posttreat
sampl
compar
felin
caliciviru
shed
detect
cat
day
detect
day
amount
shed
significantli
reduc
cat
end
studi
day
compar
begin
euthanasia
mean
surviv
time
day
one
longterm
survivor
month
rfeifnomega
group
interferon
treatment
might
effect
start
earlier
relev
treatment
cat
fip
field
howev
ifn
therapi
might
use
treatment
cat
chronic
fcov
shed
studi
requir
previous
mention
treatment
rfeifnomega
licens
sc
protocol
associ
decreas
fcov
shed
fivand
felvinfect
cat
howev
result
compar
placebo
group
conclus
antivir
still
infanc
treatment
felin
diseas
howev
new
drug
produc
human
viral
diseas
use
felin
patient
test
current
avail
drug
continu
hope
determin
effect
protocol
treatment
felin
viral
diseas
possibl
futur
applic
method
eg
ocular
versu
oral
howev
definit
conclus
drawn
without
addit
studi
also
evalu
viral
load
natur
infect
cat
random
placebocontrol
doubleblind
ifn
also
evalu
treatment
fip
random
placebocontrol
doubleblind
treatment
trial
cat
fip
treat
rfeifnomega
placebo
cat
fip
confirm
histolog
andor
immunohistochem
immunofluoresc
stain
fcov
antigen
effus
tissu
macrophag
cat
receiv
glucocorticoid
either
dexamethason
case
effus
mgkg
intrathorac
intraperiton
inject
everi
hour
prednisolon
mgkg
po
everi
hour
cat
also
receiv
either
placebo
rfeifnomega
iukg
sc
everi
hour
day
subsequ
week
statist
signific
differ
mean
surviv
time
cat
treat
rfeifnomega
versu
placebo
cat
surviv
period
day
